Cephalotaxine esters: Antileukemic advance or therapeutic failure?

Jean L. Grem, Bruce D. Cheson, Susan A. King, Brian Leyland-jones, Matthew Suffness

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Clinical trails conducted in the People's Republic of China and the United States of the antileukemic efficacy of the cephalotaxine esters are reviewed. Harringtonine has been incorporated into combination regimens for the treatment of newly diagnosed acute nonlymphocytic leukemia (ANLL) in China and activity with cephalotaxine ester has also been noted in chronic myelogenous leukemia.While the invesatment tigational agent homoharringtonine has shown some activity in the United states has wanted because of toxicity and inconvenient schedules than have U.S. studies and have been associated with less toxicity. These trails provide new information that may lead to further investigations of the cephalotaxine esters in the United States. [J Natl Cancer Inst 1988;80:1095-1103].

Original languageEnglish (US)
Pages (from-to)1095-1103
Number of pages9
JournalJournal of the National Cancer Institute
Volume80
Issue number14
DOIs
StatePublished - Sep 21 1988

Fingerprint

Esters
China
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
Appointments and Schedules
Therapeutics
cephalotaxine
Neoplasms
homoharringtonine
harringtonine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cephalotaxine esters : Antileukemic advance or therapeutic failure? / Grem, Jean L.; Cheson, Bruce D.; King, Susan A.; Leyland-jones, Brian; Suffness, Matthew.

In: Journal of the National Cancer Institute, Vol. 80, No. 14, 21.09.1988, p. 1095-1103.

Research output: Contribution to journalReview article

Grem, Jean L. ; Cheson, Bruce D. ; King, Susan A. ; Leyland-jones, Brian ; Suffness, Matthew. / Cephalotaxine esters : Antileukemic advance or therapeutic failure?. In: Journal of the National Cancer Institute. 1988 ; Vol. 80, No. 14. pp. 1095-1103.
@article{9a93e3f776f84213898249dee54bb764,
title = "Cephalotaxine esters: Antileukemic advance or therapeutic failure?",
abstract = "Clinical trails conducted in the People's Republic of China and the United States of the antileukemic efficacy of the cephalotaxine esters are reviewed. Harringtonine has been incorporated into combination regimens for the treatment of newly diagnosed acute nonlymphocytic leukemia (ANLL) in China and activity with cephalotaxine ester has also been noted in chronic myelogenous leukemia.While the invesatment tigational agent homoharringtonine has shown some activity in the United states has wanted because of toxicity and inconvenient schedules than have U.S. studies and have been associated with less toxicity. These trails provide new information that may lead to further investigations of the cephalotaxine esters in the United States. [J Natl Cancer Inst 1988;80:1095-1103].",
author = "Grem, {Jean L.} and Cheson, {Bruce D.} and King, {Susan A.} and Brian Leyland-jones and Matthew Suffness",
year = "1988",
month = "9",
day = "21",
doi = "10.1093/jnci/80.14.1095",
language = "English (US)",
volume = "80",
pages = "1095--1103",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Cephalotaxine esters

T2 - Antileukemic advance or therapeutic failure?

AU - Grem, Jean L.

AU - Cheson, Bruce D.

AU - King, Susan A.

AU - Leyland-jones, Brian

AU - Suffness, Matthew

PY - 1988/9/21

Y1 - 1988/9/21

N2 - Clinical trails conducted in the People's Republic of China and the United States of the antileukemic efficacy of the cephalotaxine esters are reviewed. Harringtonine has been incorporated into combination regimens for the treatment of newly diagnosed acute nonlymphocytic leukemia (ANLL) in China and activity with cephalotaxine ester has also been noted in chronic myelogenous leukemia.While the invesatment tigational agent homoharringtonine has shown some activity in the United states has wanted because of toxicity and inconvenient schedules than have U.S. studies and have been associated with less toxicity. These trails provide new information that may lead to further investigations of the cephalotaxine esters in the United States. [J Natl Cancer Inst 1988;80:1095-1103].

AB - Clinical trails conducted in the People's Republic of China and the United States of the antileukemic efficacy of the cephalotaxine esters are reviewed. Harringtonine has been incorporated into combination regimens for the treatment of newly diagnosed acute nonlymphocytic leukemia (ANLL) in China and activity with cephalotaxine ester has also been noted in chronic myelogenous leukemia.While the invesatment tigational agent homoharringtonine has shown some activity in the United states has wanted because of toxicity and inconvenient schedules than have U.S. studies and have been associated with less toxicity. These trails provide new information that may lead to further investigations of the cephalotaxine esters in the United States. [J Natl Cancer Inst 1988;80:1095-1103].

UR - http://www.scopus.com/inward/record.url?scp=0023683186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023683186&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.14.1095

DO - 10.1093/jnci/80.14.1095

M3 - Review article

C2 - 3045335

AN - SCOPUS:0023683186

VL - 80

SP - 1095

EP - 1103

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 14

ER -